Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

4 big analyst cuts: Snowflake downgraded twice on guidance miss

Published 26/05/2023, 12:06
Updated 26/05/2023, 12:06
© Shutterstock

© Shutterstock

By Davit Kirakosyan

Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Snowflake, MongoDB , Digital Turbine, and Annexon.

InvestingPro subscribers got these headlines in real time. Start your 7-day free trial.

Snowflake downgraded at two firms after Q1 earnings

Snowflake (NYSE:SNOW) was downgraded at two Wall Street firms after reporting its Q1 earnings, resulting in a share price drop of more than 16% yesterday, as InvestingPro reported in real-time. While Q1 results came in better than expected, the company’s outlook disappointed investors.

Rosenblatt downgraded the company to Neutral from Buy and cut its price target to $170.00 from $188.00, noting that storage headwinds slow the growth outlook.

In addition to the ongoing deal scrutiny and cloud optimization, older clients are re-evaluating data retention policies. As a result, these clients are reducing their storage requirements, which affects Snowflake’s storage revenue and compute activity.

Meanwhile, Wolfe Research downgraded the company to Peerperform from Outperform.

InvestingPro | Prevent Losses

MongoDB downgraded ahead of Q1 earnings

MongoDB (NASDAQ:MDB) shares fell more than 3% pre-market today after Guggenheim downgraded the company to Sell from Neutral while raising its price target to $210.00 from $205.00.

The company is set to report its Q1/24 earnings on June 1. Street estimates stand at $0.18 for EPS and $347.67 million for revenues.

2 more downgrades

Roth/MKM downgraded Digital Turbine (NASDAQ:APPS) to Neutral from Buy and cut its price target to $10.00 from $15.00 on growth concerns and profit erosion.

Shares plummeted more than 42% yesterday after the company reported a Q4 EPS miss and provided its Q1/24 guidance, which came in worse than the Street estimates.

BofA Securities downgraded Annexon (NASDAQ:ANNX) to Neutral from Buy and cut its price target to $3.00 from $8.00.

Shares plunged more than 59% yesterday after the company reported mixed topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA).

Get a leg up on the market: Always be the first to know with InvestingPro.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.